Efavirenz has a clinically significant effect on voriconazole pharmacokinetics
- PDF / 136,409 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 17 Downloads / 173 Views
1
■ Efavirenz has a clinically significant effect on voriconazole pharmacokinetics and coadministration of voriconazole 200mg bid with efavirenz dosages ≥ 400 mg/day "is contraindicated", according to USbased researchers. They determined that voriconazole exposure at steady state was significantly decreased following efavirenz coadministration; mean voriconazole AUC0–12 and Cmax decreased by 80% and 66%, respectively. Conversely, coadministration of voriconazole led to "moderate" increases in steadystate mean efavirenz AUC0–24 and Cmax (43% and 37%, respectively). This was a randomised, 2-period, parallel-group, multiple-dose study involving 34 healthy men; there was a placebo control for voriconazole. Liu P, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. Journal of Clinical Pharmacology 48: 801100193 73-84, No. 1, Jan 2008
0114-9954/10/1190-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 23 Feb 2008 No. 1190
Data Loading...
